DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Siemens Healthineers’s COVID-19 Antigen Self-Test; Paragon’s R3ACT Stabilization System; Pulnovo Medical’s PADN-CFDA trial; Endotronix’s PROACTIVE-HF trial; Abbott’s Proclaim XR SCS System; RTI Surgical spins off businesses Visit Post
2 Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021 Visit Post
3 Sky Medical’s Geko™ device; Fist Assist Devices obtains Breakthrough Device designation; Edwards obtains FDA approval; BD launched instrument for testing; GE acquires BK Medical; Zynex’ CM-1500; Foldax’s TRIA biopolymer heart valve Visit Post
4 Analyzing the Key Trends Driving the Biosimilar Market Growth Visit Post
5 Insights into some of the Biosimilar Drugs that are approved and launched in 2021 Visit Post
6 Aslan Pharma - IQVIA collaboration; Reata's kidney drug bardoxolone; Alzheimer’s Disease treatment update; Recordati to acquire EUSA Visit Post
7 LensGen’s Juvene Intraocular Lens; Nevro announces clinical data publications; FDA Clearance to Immunexpress’s SeptiCyte; GE unveils AI and Digital Technologies; Canon launches PIQE DLR and SilverBeam; Hyperfine’s Swoop gets FDA clearance Visit Post
8 Neurent Medical’s NEUROMARK; Brain Navi NaoTrac received European CE Mark approval; Theradaptive receives Breakthrough Medical Device Designation; HAGAR GWave awarded Breakthrough Device Designation; Fujifilm launches ColoAssist PRO Visit Post
9 Evolution in Diabetes Management Visit Post
10 An Insight Into the Weight Loss and Obesity Market Visit Post
11 An in-depth Assessment of the Top Drugs Launched by Leading Global Companies in the First Half of 2021 (H1) Visit Post
12 Biogen's ALS drug Tofersen (BIIB067); Phathom's erosive esophagitis drug trial; Vertex's islet cell therapy; Natera launches lung DNA test Visit Post
13 Recent Inclination of Pharma Companies, Emerging Pipeline Therapies Drive the IgA Nephropathy Market Share Growth Visit Post
14 Biogen’s AMD Biosimilar Gets Approval; SmartLabs Series B Funding; BARDA, Partner Therapeutics in Sepsis Space; Synlogic to Explore Sepsis Market Domain Visit Post
15 Iron Deficiency Anemia Market Growth Anticipated to Fuel at a CAGR of 3.7% by 2030 Visit Post
16 Which Pipeline Therapy is Expected to Capture the Eyeballs in the Phenylketonuria Market? Visit Post
17 Abiomed’s Impella ECP; Helius’s PoNS Device; Smart Meter’s iGlucose BGM; XACT’s CT-Guided Percutaneous Procedures; BD’s Veritor At-Home COVID-19 Test; Delfi’s Liquid Biopsy Visit Post
18 Ascendis's SKYTROFA; MicroTransponder’s VNS System (Vivistim); BioMarin's Voxzogo; Zimmer-Canary's Smart Knee Implant; COVID-19 impact on Solid Organ Transplants Visit Post
19 Boston Scientific’s EkoSonic; FDA clearance for EXALT; Kestra Medical’s ASSURE; ZOLL Next-Generation remedē system; CytoSorbents' DrugSorb-ATR; Fujifilm-Lunit collaboration Visit Post
20 New Approaches and Evolutions to Reshape the Diabetes Management and Care Visit Post
21 Primary Hyperoxaluria Market Size Observes Growth with a Substantial CAGR Visit Post
22 Nevro's Spinal Cord Stimulation; Boston's PINNACLE FLX; NuVasive's Modulus ALIF; J&J's VERITAS Vision System; Medtronic's DCB Catheter; AngelMed's Heart Attack Warning System Visit Post
23 BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera’s nerve implant gets a $65M boost Rivus’ therapy nabs $35M Visit Post
24 Cost-effectiveness, Advanced Technology, Rising Demand Pushes the Insulin Delivery Devices Market Visit Post
25 MedTech Market Industry: Approval of Devices, Therapy Address Market Needs | Clinical Outcomes Create New Value Visit Post
26 Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor’s Bleak Future Visit Post
27 Diabetic Macular Edema Therapy Market to Witness Significant Impact in the Foreseeable Future Visit Post
28 Global Chronic Pain Associated With Painful Diabetic Neuropathy Market Landscape Visit Post
29 Understanding The Increasing Prevalence Of Diabetes And Its Complications Visit Post
30 Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M Visit Post
31 Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO Visit Post
32 Diagnosing At-Home: Are At-Home Diagnostic Tools The New Trends? Visit Post
33 Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer Visit Post
34 Verily - Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis Visit Post
35 Notorious Hyperkalemia: What are the causes, signs and new treatments? Visit Post
36 Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate Visit Post
37 The Obesity Pandemic: What can we do about it? Visit Post
38 A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica Visit Post
39 Treating Patients with Software: Digital Therapeutics Visit Post
40 Will Wearable Devices be Streamlined in Healthcare? Visit Post
41 Creating Future of MedTech Industry with Artificial Intelligence Visit Post
42 Key Companies To Keep an Eye on for Pipeline Therapies in Osteosarcoma Market in the Next Decade Visit Post
43 Pitfalls of Current Osteosarcoma Treatment Approaches Visit Post
44 What Does The Acromegaly Pipeline Have Up In Its Sleeve? Visit Post
45 What are the Top Five Leading Causes of Deaths in the World? Visit Post
46 Metabolic Acidosis: Counting The Unmeasured Anions And Closing the Gap In Blood Serum Visit Post
47 The Question That Remains Unanswered: What Might Be Causing Alzheimer’s? Visit Post
48 Gene-edited T cells for diabetes treatment; Pliant raised $144 million; Accent, AstraZeneca aim RNA modifiers in cancer deal; NodThera Raises $55M; Visit Post
49 Precision Medicine: An emerging approach to conventional treatment Visit Post
50 Algernon's NP-120; FDA nod to 4DMedical tool; SaNOtize's NORSTM trial; Pole's capital increase Visit Post
51 Hunter Syndrome Market experiences a positive push as the pharma companies spot the untapped opportunities Visit Post
52 AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes Visit Post
53 Niacin fights Glioblastoma, iTeos nets $125M, Pandion reels in $80M, Brii, Chinese partner, FDA to speed up COVID-19 therapies Visit Post
54 Bioelectronic Medicine: Applications and Future Prospects Visit Post
55 Dubai: A leading and exciting pharma hotspot Visit Post
56 Booming Healthcare sector in MENA: Lucrative opportunity for Global pharma players Visit Post
57 Potential of Digital therapeutics and increasing CVDs Visit Post
58 Thyroid awareness month Visit Post
59 Tepezza receives approval; a new way to treat Alzheimer’s Visit Post
60 Cumberland’s methotrexate product gets approval in the US; Baker Brothers purchases stake in Kodiak’s KSI-301; Sanofi offloads Seprafilm unit to Baxter Visit Post
61 Toujeo to treat Type 1 Diabetes; TauRx for Alzheimer’s patients Visit Post
62 GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion Visit Post
63 Nordisk ties up with Dicerna; Pfizer's drug gets FDA nod Visit Post
64 World Diabetes Day | 2019 Visit Post
65 FDA declines the approval of Lipocine’s testosterone drug; Novartis Sandoz to buy Aspen Pharmacare Japanese Unit Visit Post
66 Evotec, Vifor Pharma collaborates to cure kidney diseases; AZ takes major steps to advance pharma and medicine R&D in China; Amneal licenses-in a Myasthenia Gravis drug from Kashiv BioSciences Visit Post
67 First oral GLP-1 treatment approved for type2 Diabetes Visit Post
68 Hyperthyroidism Treatment Market and Drugs Visit Post
69 Fujifilm acquires global rights to Cynata's novel therapy for GvHD; Themis raises EURO 40 million for Chikungunya vaccine; Bayer to license One Drop's digital diabetes platform Visit Post
70 Genenta Sciences raises USD 14.54M; GSK announces to buy Sitari Pharmaceuticals; Mallinckrodt to Sell BioVectra for USD 25M; Lexicon to receive USD 260M from terminated diabetes partnership  Visit Post
71 Diabetic Gastroparesis Market Outlook Visit Post
72 Baqsimi wins FDA nod for Hypoglycemia; Freenome captures USD 160M; FDA approval for Ruxience for leukaemia Visit Post
73 FDA approves Lyrica; CRH Medical purchase Crystal River Anesthesia Visit Post
74 NICE endorsement for Pfizer’s Vizimpro; Eisai, Dundee targets Cancer; Capital raise for AgaMatrix Visit Post
75 Teplizumab delays the progression of Type 1 Diabetes Visit Post
76 European Commission gives a nod to Zynquista for type 1 diabetes in adults Visit Post
77 Notizia Visit Post
78 Notizia Visit Post
79 AgomAb Therapeutics raises $23.5M; Allergan's eye drug; Good news for the patients; Dyne Therapeutics comes to life Visit Post
80 Notizia Visit Post
81 Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate; Blaze Bioscience nets $5M Visit Post
82 Human cells reprogrammed to create insulin in diabetic mice Visit Post
83 Acromegaly Visit Post
84 BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M Visit Post
85 Lilly remunerates AC Immune; Akero adds $70M; Ra Pharma $100M Visit Post
86 Notizia Visit Post
87 World Diabetes Day | 2018 Visit Post
88 World Diabetes Day Visit Post
89 Notizia Visit Post
90 Notizia Visit Post
91 Notizia Visit Post
92 Notizia Visit Post
93 SNIPPET Visit Post
94 Notizia Visit Post
95 Commercial Visit Post
96 Digital Pill: A new frontier in digital healthcare all set to take-off Visit Post
97 Commercial Visit Post
98 Celiac vaccine trial; New discovery in Nicotine; Nabriva lines up FDA filing; Rare Disease drug development accelerating Visit Post
99 Nonalcoholic Steatohepatitis (NASH): Highly Epidemic Visit Post
100 Meeting the Unmet: Nonalcoholic Steatohepatitis (NASH) Visit Post
101 Business Cocktail Visit Post
102 Notizia Visit Post
103 Novo petitions FDA;J&J invests; Xarelto’s trial; Roche's Tecentriq Visit Post
104 Therapeutics and Celgene to develop therapies; Takeda’s expansion; J&J hopes to limit; Tech Prize for genome sequencing; Endocyte’s late-stage prostate cancer deal Visit Post
105 Business CockTail Visit Post
106 Sanofi invests; ICER pitches; $6M in NIH; Pfizer, Roche cancer drug pricing Visit Post
107 Invokana matches; Xultophy beats; Lilly and BI follow; Tresiba matches Visit Post
108 Merck's Remicade; Sanofi, Regeneron set Kevzara; Novartis to sever; Teva puts women's health Visit Post
109 Humira’s patent; Teva laying off; GSK aims; Thermo acquires Patheon; J& J's Invokana Visit Post
110 Cancer, diabetes and eczema on list; AbbVie's Humira; Teva weighs $2B; Fresenius in buyout talks Visit Post
111 Acromegaly and Gigantism: It’s all about excessive Growth Hormone… Visit Post
112 A Probiotic drink from the gut microbiome of an elite athlete Visit Post
113 Biogen triumphs; Lilly, Pfizer, Ipsen back; Court nixes; Mylan EpiPen recall Visit Post
114 Cushing’s Syndrome: Cortisol Plethora Visit Post
115 AstraZeneca announces; Trivitron launches; BrainStorm Cell Therapeutics validates Visit Post
116 Sanofi sues Novo; Allergan gets help; Actelion snubs; Impax CEO Wilkinson out Visit Post
117 Glaxo replaces ViiV; Lilly nets; AstraZeneca shuffles off; Gazyva aims to beat Visit Post
118 EC grants; Pfizer cuts; 27 medicines sold; Keytruda nabs Visit Post
119 Fresenius Kabi introduced Bivalirudin; Envigo Launches; Mylan's MAA accepted; Pricing hit pharma Visit Post
120 Biosimilar Market in India Visit Post
121 Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV Visit Post
122 Sun Pharma & ICGEB announce collaboration; Boehringer Ingelheim and Lupin Sign deal; Daiichi Sankyo Announces; Catalent Pharma Solutions partners with Samsung Bioepis; Celltrion Healthcare and Teva enters into exclusive business collaboration agreement Visit Post
123 Lupin acquired; FDA grants approval; NATCO gets approval; Wockhardt Ltd. gets import alert; Patent fight Visit Post
124 Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
125 Small interfering RNA (siRNA) Therapeutics Visit Post
126 DelveInsight’s Metabolic disorders based Gene Therapy Reports Visit Post
127 EMA Biosimilars Approvals Visit Post